Literature DB >> 17523724

Pharmacokinetics of Losartan and its Active Metabolite EXP3174 in Healthy Iranian Subjects.

Hossein Amini1, Abolhassan Ahmadiani, Maryam Moazenzadeh.   

Abstract

Entities:  

Year:  2004        PMID： 17523724     DOI： 10.2165/00044011-200424100-00008

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  13 in total

1.  Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174.

Authors:  J B McCrea; A Cribb; T Rushmore; B Osborne; L Gillen; M W Lo; S Waldman; T Bjornsson; S Spielberg; M R Goldberg
Journal:  Clin Pharmacol Ther       Date:  1999-03       Impact factor: 6.875

2.  Allele frequency of CYP2C9 gene polymorphisms in Iran.

Authors:  F Peyvandi; M Spreafico; M Karimi; S Zeinali; P M Mannucci; A Bianchi Bonomi
Journal:  Thromb Haemost       Date:  2002-11       Impact factor: 5.249

3.  Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.

Authors:  P C Wong; W A Price; A T Chiu; J V Duncia; D J Carini; R R Wexler; A L Johnson; P B Timmermans
Journal:  J Pharmacol Exp Ther       Date:  1990-10       Impact factor: 4.030

4.  Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.

Authors:  K M Kaukonen; K T Olkkola; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  1998-02       Impact factor: 2.953

5.  Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.

Authors:  Umit Yasar; Cecilia Forslund-Bergengren; Gunnel Tybring; Pedro Dorado; Adrián Llerena; Folke Sjöqvist; Erik Eliasson; Marja-Liisa Dahl
Journal:  Clin Pharmacol Ther       Date:  2002-01       Impact factor: 6.875

6.  Role of CYP2C9 polymorphism in losartan oxidation.

Authors:  G Tybring; M Hidestrand; M Oscarson; M Ingelman-Sundberg; M L Dahl; E Eliasson
Journal:  Drug Metab Dispos       Date:  2001-07       Impact factor: 3.922

7.  The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers.

Authors:  A M Meadowcroft; K M Williamson; J H Patterson; A L Hinderliter; J A Pieper
Journal:  J Clin Pharmacol       Date:  1999-04       Impact factor: 3.126

8.  Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection.

Authors:  P K Yeung; A Jamieson; G J Smith; D Fice; P T Pollak
Journal:  Int J Pharm       Date:  2000-08-25       Impact factor: 5.875

9.  Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans.

Authors:  M Ohtawa; F Takayama; K Saitoh; T Yoshinaga; M Nakashima
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

10.  Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension.

Authors:  M Sasaki; A Fujimura; K Harada; K Sunaga; A Ebihara
Journal:  J Clin Pharmacol       Date:  1996-05       Impact factor: 3.126
View more
  2 in total

1.  Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension.

Authors:  Jian-Qi Zhang; Guo-Hong Yang; Xin Zhou; Jun-Xiang Liu; Rui Shi; Yan Dong; Shao-Bo Chen; Yu-Ming Li
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

2.  Allisartan ameliorates vascular remodeling through regulation of voltage-gated potassium channels in hypertensive rats.

Authors:  Xiaoqin Zhang; Ziying Zhao; Chunfang Xu; Fengping Zhao; Zhiqiang Yan
Journal:  BMC Pharmacol Toxicol       Date:  2021-06-09       Impact factor: 2.483
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.